专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US07288545B2 Piperazinedione compounds 失效
公开(公告)号：US07288545B2
公开(公告)日：2007-10-30
申请号：US10689865
申请日：2003-10-20
申请人： Che-Ming Teng , Hui-Po Wang , Eric I. C. Li , On Lee , Jih-Hwa Guh , Huei-Ting Chen , Ya-Bing Fan , Ya-Lan Chen
发明人： Che-Ming Teng , Hui-Po Wang , Eric I. C. Li , On Lee , Jih-Hwa Guh , Huei-Ting Chen , Ya-Bing Fan , Ya-Lan Chen
IPC分类号： A61K31/496 , C07D405/14
CPC分类号： C07D401/06 , C07D409/14
摘要： This invention relates to a method for treating an angiogenesis-related disease. The method includes administering to a subject in need thereof an effective amount of a piperazinedione compound having the formula: In the above formula, each of and , independently, is a single bond or a double bond; A is H or CH(RaRb) when is a single bond, or C(RaRb) when is a double bond; Z is CH(RcRd) when is a single bond, or C(RcRd) when is a double bond; each of R1 and R2, independently, is H, C(O)Re, C(O)ORe, C(O)NReRf, or SO2Re; and each of Ra, Rb, Rc, Rd, Re, and Rf, independently, is H, C1-C6 alkyl, aryl, heteroaryl, C3-C8 cycloalkyl, or C3-C8 heterocycloalkyl; or Ra and Rb taken together are C3-C8 cycloalkyl, C3-C8 heterocycloalkyl, aryl, or heteroaryl; or R1 and Ra or R1 and Rb taken together are C3-C8 cycloalkyl, C3-C8 heterocycloalkyl, aryl, or heteroaryl; provided that one of Rc and Rd is aryl or heteroaryl.

2. 发明授权

US06635649B2 Piperazinedione compounds 失效
标题翻译：哌嗪二酮化合物
公开(公告)号：US06635649B2
公开(公告)日：2003-10-21
申请号：US09851077
申请日：2001-05-08
申请人： Che-Ming Teng , Hui-Po Wang , Eric I. C. Li , On Lee , Jih-Hwa Guh , Huei-Ting Chen , Ya-Bing Fan , Ya-Lan Chen
发明人： Che-Ming Teng , Hui-Po Wang , Eric I. C. Li , On Lee , Jih-Hwa Guh , Huei-Ting Chen , Ya-Bing Fan , Ya-Lan Chen
IPC分类号： A61K31496
CPC分类号： C07D401/06 , C07D409/14
摘要： Piperazinedione compounds of the formula: Each of and and independently, is a single bond or a double bond; A is H or CH(RaRb) when is a single bond, or C(RaRb) when is a double bond; Z is R3O—(Ar)—B, in which B is CH(Rc) when is a single bond, or C(Rc) when is a double bond; Ar is heteroaryl; and R3 is H, alkyl, aryl, heteroaryl, C(O)Rd, C(O)ORd, C(O)NRdRe, or SO2Rd; each of R1 and R2, independently, is H, C(O)Rd, C(O)ORd, C(O)NRdRe, or SO2Rd; and each of Ra, Rb, Rc, Rd, and Re, independently, is H, alkyl, aryl, heteroaryl, cyclyl, or heterocyclyl. Optionally, Ra and Rb taken together are cyclyl or heterocyclyl; and, also optionally, R1 and Ra or R1 and Rb taken together are cyclyl or heterocyclyl. Also disclosed is a method for treating tumor with the above described piperazinedione compounds.
摘要翻译：哌嗪二酮化合物，分别为：＆lt; CUSTOM-CHARACTER FILE =“US06635649-20031021-P00900.TIF”ALT =“custom character”HE =“20”WI =“20”ID =“CUSTOM-CHARACTER-00001”/ >和或双键; 当是单键，或C（R a R b）当为双键时; 当是单键或C（R ）”ALT =“自定义字符”HE =“20”WI =“20”ID =“CUSTOM-CHARACTER-00005”/>是双键; Ar是杂芳基; 且R 3为H，烷基，芳基，杂芳基，C（O）R d，C（O）OR d，C（O）NR d R e或SO 2 R d; R 1和R 2各自独立地是H，C（O）R d，C（O）OR d，C（O）NR d R e或SO 2 R ; R a，R b，R c，R d和R e各自独立地是H，烷基，芳基，杂芳基，环基或杂环基。任选地，R 5和R b一起是环基或杂环基; 并且还可任选地，R 1和R 5'或R 1和R b一起是环基或杂环基。还公开了用上述哌嗪二酮化合物治疗肿瘤的方法。

3. 发明申请

US20050119278A1 Anti-angiogenesis methods 审中-公开
标题翻译：抗血管生成方法
公开(公告)号：US20050119278A1
公开(公告)日：2005-06-02
申请号：US10930065
申请日：2004-08-30
申请人： Che-Ming Teng , Sheng-Chu Kuo , Fang-Yu Lee , Shiow-Lin Pan , Jih-Hwa Guh
发明人： Che-Ming Teng , Sheng-Chu Kuo , Fang-Yu Lee , Shiow-Lin Pan , Jih-Hwa Guh
IPC分类号： A61K31/416 , A61K31/4745 , A61K31/519 , A61K31/4162 , A61K31/4439 , A61K31/506
CPC分类号： A61K31/4745 , A61K31/416 , A61K31/519
摘要： A method for inhibiting cell proliferation, cell migration, or tube formation induced by an angiogenic factor. The method includes administrating to a subject in need thereof an effective amount of a compound of the formula: wherein A is H or in which n is 0, 1, 2, or 3; each of Ar1, Ar2, and Ar3, independently, is phenyl, thienyl, furyl, pyrrolyl, pyridinyl, or pyrimidinyl; each of R1, R2, R3, R4, R5, and R6, independently, is R, nitro, halogen, C(O)OR, C(O)SR, C(O)NRR′, (CH2)mOR, (CH2)mSR, (CH2)mNRR′, (CH2)mCN, (CH2)mC(O)OR, (CH2)mCHO, (CH2)mCH═NOR, or R1 and R2 together, R3 and R4 together, or R5 and R6 together are O(CH2)mO, in which each of R and R′, independently, is H, alkyl, aryl, heteroaryl, cyclyl, or heterocyclyl; and m is 0, 1, 2, 3, 4, 5, or 6, and n is 0, 1, 2, or 3.
摘要翻译：一种抑制血管生成因子诱导的细胞增殖，细胞迁移或管形成的方法。该方法包括向有需要的受试者施用有效量的下式化合物：其中A为H或其中n为0,1,2或3; Ar 1，Ar 2和Ar 3各自独立地是苯基，噻吩基，呋喃基，吡咯基，吡啶基或嘧啶基; R 1，R 2，R 3，R 4，R 5，和/或R 3中的每一个 >和R 6独立地是R，硝基，卤素，C（O）OR，C（O）SR，C（O）NRR'，（CH 2）（CH 2）m，或（CH 2）m SR，（CH 2 2）m， C（O）OR（CH 2 CH 2）m C（O）OR（CH 2），（CH 2 CH 2）m CHO，（CH 2 CH 2）m CH或NOR，或R 1， 1个和R 2个在一起，R 3和R 4一起，或者R 5和R 5 一起是O（CH 2）2 O，其中R和R'各自独立地是H，烷基，芳基，杂芳基，环基或杂环基; m为0,1,2,3,4,5或6，n为0,1,2或3。

4. 发明申请

US20070149554A1 Cancer chemotherapy 审中-公开
标题翻译：癌症化疗
公开(公告)号：US20070149554A1
公开(公告)日：2007-06-28
申请号：US11643103
申请日：2006-12-21
申请人： Sheng-Chu Kuo , Che-Ming Teng , Fang-Yu Lee , Shiow-Lin Pan , Jih-Hwa Guh
发明人： Sheng-Chu Kuo , Che-Ming Teng , Fang-Yu Lee , Shiow-Lin Pan , Jih-Hwa Guh
IPC分类号： A61K31/519 , A61K31/4745 , A61K31/4162
CPC分类号： A61K45/06 , A61K31/34 , A61K31/38 , A61K31/416 , A61K31/4162 , A61K31/4745 , A61K31/519 , A61K2300/00
摘要： A method for treating cancer, which includes administrating to a subject in need thereof an effective amount of a chemotherapeutic agent and an effective amount of a compound of the formula: in which, A is H or each of Ar1, Ar2, and Ar3, independently, is phenyl, thienyl, furyl, pyrrolyl, pyridinyl, or pyrimidinyl; each of R1, R2, R3, R4, R5, and R6, independently, is R, nitro, halogen, C(O)OR, C(O)SR, C(O)NRR′, (CH2)mOR, (CH2)mSR, (CH2)mNRR′, (CH2)mCN, (CH2)mC(O)OR, (CH2)mCHO, (CH2)mCH═NOR, (CH2)mC(O)N(OR)R′, N(OR)R′, or R1 and R2 together, R3 and R4 together, or R5 and R6 together are O(CH2)mO, in which each of R and R′, independently, is H or C1˜C6 alkyl; and m is 0, 1, 2, 3, 4, 5, or 6, and n is 0, 1, 2, or 3.
摘要翻译：一种治疗癌症的方法，其包括向有需要的受试者施用有效量的化学治疗剂和有效量的下式化合物：其中A为H或Ar 1 / Ar 2，Ar 3和Ar 3独立地是苯基，噻吩基，呋喃基，吡咯基，吡啶基或嘧啶基; R 1，R 2，R 3，R 4，R 5，和/或R 3中的每一个 >和R 6独立地是R，硝基，卤素，C（O）OR，C（O）SR，C（O）NRR'，（CH 2）（CH 2）m，或（CH 2）m SR，（CH 2 2）m， C（O）OR（CH 2 CH 2）m C（O）OR（CH 2），（CH 2 CH 2）m CHO，（CH 2 CH 2）m CH，或CH 2，（CH 3） C（O）N（OR）R'，N（OR）R'或R 1和R 2' 一起，R 3和R 4一起，或者R 5和R 6一起是O（CH 其中R和R'各自独立地是H或C 1〜C 6，烷基; m为0,1,2,3,4,5或6，n为0,1,2或3。

5. 发明申请

US20070142449A1 Angiogenesis inhibitors 审中-公开
标题翻译：血管生成抑制剂
公开(公告)号：US20070142449A1
公开(公告)日：2007-06-21
申请号：US11648952
申请日：2007-01-03
申请人： Che-Ming Teng , Sheng-Chu Kuo , Fang-Yu Lee , Shiow-Lin Pan , Jih-Hwa Guh
发明人： Che-Ming Teng , Sheng-Chu Kuo , Fang-Yu Lee , Shiow-Lin Pan , Jih-Hwa Guh
IPC分类号： A61K31/4162 , A61K31/519 , A61K31/4745
CPC分类号： A61K31/416 , A61K31/4162 , A61K31/4745 , A61K31/519
摘要： A method for treating an angiogenesis-related disorder or cancer. The method includes administrating to a subject in need thereof an effective amount of a compound of the formula: Each of Ar1, Ar2, and Ar3, independently, is phenyl, thienyl, furyl, pyrrolyl, pyridinyl, or pyrimidinyl; each of R1, R2, R3, R4, R5, and R6, independently, is R, nitro, halogen, C(O)OR, C(O)SR, C(O)NRR′, (CH2)mOR, (CH2)mSR, (CH2)mNRR′, (CH2)mCN, (CH2)mC)O)OR, (CH2)mCHO, (CH2)mCH═NOR, or R1 and R2 together, R3 and R4 together, or R5 and R6 together are O(CH2)mO, in which each of R and R′, independently, is H or C1˜C6 alkyl; and m is 0, 1, 2, 3, 4, 5, or 6, and n is 0, 1, 2, or 3.
摘要翻译：一种治疗血管生成相关病症或癌症的方法。该方法包括向有需要的受试者施用有效量的下式化合物：Ar 1，Ar 2和Ar 3中的每一个，独立地是苯基，噻吩基，呋喃基，吡咯基，吡啶基或嘧啶基; R 1，R 2，R 3，R 4，R 5，和/或R 3中的每一个 >和R 6独立地是R，硝基，卤素，C（O）OR，C（O）SR，C（O）NRR'，（CH 2）（CH 2）m，或（CH 2）m SR，（CH 2 2）m， N，NRR'，（CH 2 CH 2）m CN，（CH 2 CH 2）m C（O）OR ，（CH 2 CH 2）m CHO，（CH 2 CH 2）m CH或NOR，或R 1， 1个和R 2个在一起，R 3和R 4一起，或者R 5和R 5 一起是O（CH 2 CH 2）m O，其中R和R'各自独立地是H或C 1 -C 6烷基， C 1 -C 6烷基; m为0,1,2,3,4,5或6，n为0,1,2或3。

6. 发明授权

US06943186B2 Methods of treating sepsis 失效
标题翻译：治疗败血症的方法
公开(公告)号：US06943186B2
公开(公告)日：2005-09-13
申请号：US10350794
申请日：2003-01-24
申请人： Che-Ming Teng , Shiow-Lin Pan , Jih-Hwa Guh , Sheng-Chu Kuo , Fang-Yu Lee
发明人： Che-Ming Teng , Shiow-Lin Pan , Jih-Hwa Guh , Sheng-Chu Kuo , Fang-Yu Lee
IPC分类号： A61K31/416 , A61K31/4162 , A61P9/00 , A61P31/00 , A61P31/04 , A61P43/00 , C07D231/56 , C07D405/04 , C07D491/04 , C07D491/056 , C07D495/04
CPC分类号： C07D491/04 , C07D231/56 , C07D405/04 , C07D495/04
摘要： The present invention features a method for treating sepsis. The method includes administrating to a subject in need thereof an effective amount of a fused pyrazolyl compound of formula (I): A is H, C1˜C6 alkyl, or in which n is 0, 1, 2, or 3; each of Ar1, Ar2, and Ar3, independently, is phenyl, pyridinyl, thienyl, furyl, or pyrrolyl; and each of R1, R2, R3, R4, R5, and R6, independently, is XYZ; or R1 and R2 together, R3 and R4 together, or R5 and R6 together are O(CH2)1-6O; in which X is a bond or C1˜C6 alkylene, Y is a bond, O, S, OC(O), OC(O)(CH2)1-6C(O)O, C(O)O, C(O)S, C(O)NH, C(O)NC1˜C6 alkyl, NH, or NC1˜C6 alkyl, and Z is H, halogen, CN, NO2, or C1˜C6 alkyl; and provided that one of R3 and R4 is not H.
摘要翻译：本发明的特征在于一种治疗败血症的方法。该方法包括向有需要的受试者施用有效量的式（I）的稠合吡唑基化合物：A是H，C 1 -C 6烷基，或其中n为0,1,2或3; Ar 1，Ar 2和Ar 3各自独立地是苯基，吡啶基，噻吩基，呋喃基或吡咯基; 并且R 1，R 2，R 3，R 4，R 5， SUB>和R 6独立地是XYZ; 或R 1和R 2共同在一起，R 3和R 4一起，或R 5， / SUB和R 6一起是O（CH 2）2 - 其中X是一个键或C 1 -C 6亚烷基，Y是一个键，O，S，OC（O），OC（O）（CH

7. 发明授权

US08501957B2 Benzimidazole compounds and their use as anticancer agents 有权
标题翻译：苯并咪唑化合物及其作为抗癌剂的用途
公开(公告)号：US08501957B2
公开(公告)日：2013-08-06
申请号：US12635206
申请日：2009-12-10
申请人： Chih-Shiang Chang , Jih-Hwa Guh , Che-Ming Teng , Shiow-Lin Pan , Wei-Ling Chang , Ju-Fang Liu , Kai-Wei Chang , Sheng-Chu Kuo
发明人： Chih-Shiang Chang , Jih-Hwa Guh , Che-Ming Teng , Shiow-Lin Pan , Wei-Ling Chang , Ju-Fang Liu , Kai-Wei Chang , Sheng-Chu Kuo
IPC分类号： A61K31/4184 , C07D235/18
CPC分类号： A61K31/4184 , A61K31/4439 , A61K31/454 , A61K31/496 , A61K31/5377 , C07D235/06 , C07D235/10 , C07D235/18 , C07D401/04 , C07D401/12 , C07D403/06 , C07D403/12 , C07D405/04 , C07D405/14 , C07D409/04
摘要： Benzimidazole compounds of formula (I): wherein R1, R2, R3, R4, R5, X, Y, Z1, and Z2 are defined herein. Also disclosed is a method for treating cancer with benzimidazole compounds.
摘要翻译：式（I）的苯并咪唑化合物：其中R1，R2，R3，R4，R5，X，Y，Z1和Z2如本文所定义。还公开了用苯并咪唑化合物治疗癌症的方法。

8. 发明申请

US20050209252A1 Cancer treatment 审中-公开
标题翻译：癌症治疗
公开(公告)号：US20050209252A1
公开(公告)日：2005-09-22
申请号：US11132756
申请日：2005-05-18
申请人： Che-Ming Teng , Sheng-Chu Kuo , Fang-Yu Lee , Shiow-Lin Pan , Jih-Hwa Guh
发明人： Che-Ming Teng , Sheng-Chu Kuo , Fang-Yu Lee , Shiow-Lin Pan , Jih-Hwa Guh
IPC分类号： C07D405/04 , A61K31/416 , A61K31/4162 , A61K31/4745 , A61K31/519 , A61P1/04 , A61P3/06 , A61P3/10 , A61P9/00 , A61P9/10 , A61P15/00 , A61P17/06 , A61P19/02 , A61P27/02 , A61P29/00 , A61P35/00
CPC分类号： A61K31/416 , A61K31/4162 , A61K31/4745 , A61K31/519
摘要： This invention relates to a method for treating cancer including administrating to a subject in need thereof an effective amount of a compound of the formula: wherein, A is H or each of Ar1, Ar2, and Ar3, independently, is phenyl, thienyl, furyl, pyrrolyl, pyridinyl, or pyrimidinyl; each of R1, R2, R3, R4, R5, and R6, independently, is R, nitro, halogen, C(O)OR, C(O)SR, C(O)NRR′, (CH2)mOR, (CH2)mSR, (CH2)mNRR′, (CH2)mCN, (CH2)mC(O)OR, (CH2)mCHO, (CH2)mCH═NOR, (CH2)mC(O)N(OR)R′, N(OR)R′, or R1 and R2 together, R3 and R4 together, or R5 and R6 together are O(CH2)mO, in which each of R and R′, independently, is H or C1˜C6 alkyl; and m is 0, 1, 2, 3, 4, 5, or 6, and n is 0, 1, 2, or 3.
摘要翻译：本发明涉及一种治疗癌症的方法，包括向有需要的受试者施用有效量的下式化合物：其中A为H或Ar 1，Ar 2的每一个 R 3和R 3独立地是苯基，噻吩基，呋喃基，吡咯基，吡啶基或嘧啶基; R 1，R 2，R 3，R 4，R 5，和/或R 3中的每一个 >和R 6独立地是R，硝基，卤素，C（O）OR，C（O）SR，C（O）NRR'，（CH 2）（CH 2）m，或（CH 2）m SR，（CH 2 2）m， C（O）OR（CH 2 CH 2）m C（O）OR（CH 2），（CH 2 CH 2）m CHO，（CH 2 CH 2）m CH，或CH 2，（CH 3） C（O）N（OR）R'，N（OR）R'或R 1和R 2' 一起，R 3和R 4一起，或者R 5和R 6一起是O（CH 其中R和R'各自独立地是H或C 1〜C 6，烷基; m为0,1,2,3,4,5或6，n为0,1,2或3。

9. 发明授权

US07754751B2 Preferential inhibition of release of pro-inflammatory cytokines 失效
标题翻译：优先抑制促炎细胞因子的释放
公开(公告)号：US07754751B2
公开(公告)日：2010-07-13
申请号：US11080384
申请日：2005-03-15
申请人： Che-Ming Teng , Jih-Hwa Guh , Shiow-Lin Pan , Sheng-Chu Kuo , Fang-Yu Lee
发明人： Che-Ming Teng , Jih-Hwa Guh , Shiow-Lin Pan , Sheng-Chu Kuo , Fang-Yu Lee
IPC分类号： A01N43/56 , C07D231/10 , C07D231/12
CPC分类号： A61K31/4162 , A61K31/415
摘要： A method for preferentially inhibiting release of pro-inflammatory cytokines over release of anti-inflammatory cytokines using a fused pyrazolyl compound of formula (I): A is R or in which R is H, alkyl, aryl, cyclyl, heteroaryl, or heterocyclyl; each of Ar1, Ar2, and Ar3, independently, is phenyl, thienyl, furyl, or pyrrolyl; each of R1, R2, R3, R4, R5, and R6, independently, is R′, nitro, halogen, —C(O)—OR′, —C(O)—SR′, —C(O)—NR′R″, —(CH2)mOR′, —(CH2)mSR′, —(CH2)mNR′R″, —(CH2)mCN, —(CH2)mC(O)—OR′, —(CH2)mC(O)H, or R1 and R2 together, R3 and R4 together, or R5 and R6 together are —O(CH2)nO—, in which each of R′ and R″, independently, is H, alkyl, cyclyl, aryl, heteroaryl, heterocyclyl; and m is 0, 1, 2, 3, 4, 5, or 6; and n is 1, 2, or 3. This invention also covers a method of inhibiting activity of NF-κB with such a compound.
摘要翻译：使用式（I）的稠合吡唑基化合物优先抑制促炎细胞因子释放超过抗炎细胞因子释放的方法：A是R或其中R是H，烷基，芳基，环基，杂芳基或杂环基; Ar 1，Ar 2和Ar 3各自独立地是苯基，噻吩基，呋喃基或吡咯基; R 1，R 2，R 3，R 4，R 5和R 6各自独立地是R'，硝基，卤素，-C（O）-OR'， - C（O）-SR' “（CH 2）m R”， - （CH 2）m SRR'， - （CH 2）m NR R'， - （CH 2）m CN， - （CH 2）m C（O）（O）H，或R 1和R 2一起，R 3和R 4一起，或者R 5和R 6一起是-O（CH 2）n O-，其中R'和R“各自独立地是H，烷基，环基，芳基，杂芳基，杂环基; m为0,1,2,3,4,5或6; 并且n为1,2或3.本发明还涵盖了用这种化合物抑制NF-κB活性的方法。

10. 发明授权

US07166293B2 Angiogenesis inhibitors 有权
标题翻译：血管生成抑制剂
公开(公告)号：US07166293B2
公开(公告)日：2007-01-23
申请号：US10147445
申请日：2002-05-16
申请人： Che-Ming Teng , Sheng-Chu Kuo , Fang Yu Lee , Shiow-Lin Pan , Jih-Hwa Guh
发明人： Che-Ming Teng , Sheng-Chu Kuo , Fang Yu Lee , Shiow-Lin Pan , Jih-Hwa Guh
IPC分类号： A01N25/00 , A01N25/32
CPC分类号： A61K31/4162 , A61K31/416 , A61K31/4745 , A61K31/519
摘要： A method for treating an angiogenesis-related disorder. The method includes administrating to a subject in need thereof an effective amount of a compound of the formula: Each of Ar1, Ar2, and Ar3, independently, is phenyl, thienyl, furyl, pyrrolyl, pyridinyl, or pyrimidinyl; each of R1, R2, R3, R4, R5, and R6, independently, is R, nitro, halogen, C(O)OR, C(O)SR, C(O)NRR′, (CH2)mOR, (CH2)mSR, (CH2)mNRR′, (CH2)mCN, (CH2)mC(O)OR, (CH2)mCHO, (CH2)mCH═NOR, or R1 and R2 together, R3 and R4 together, or R5 and R6 together are O(CH2)mO, in which each of R and R′, independently, is H or C1˜C6 alkyl; and m is 0, 1, 2, 3, 4, 5, or 6, and n is 0, 1, 2, or 3.
摘要翻译：一种治疗血管生成相关病症的方法。该方法包括向有需要的受试者施用有效量的下式化合物：Ar 1，Ar 2和Ar 3中的每一个，独立地是苯基，噻吩基，呋喃基，吡咯基，吡啶基或嘧啶基; R 1，R 2，R 3，R 4，R 5，和/或R 3中的每一个 >和R 6独立地是R，硝基，卤素，C（O）OR，C（O）SR，C（O）NRR'，（CH 2）（CH 2）m，或（CH 2）m SR，（CH 2 2）m， C（O）OR（CH 2 CH 2）m C（O）OR（CH 2），（CH 2 CH 2）m CHO，（CH 2 CH 2）m CH或NOR，或R 1， 1个和R 2个在一起，R 3和R 4一起，或者R 5和R 5 一起是O（CH 2 CH 2）m O，其中R和R'各自独立地是H或C 1 -C 6烷基， C 1 -C 6烷基; m为0,1,2,3,4,5或6，n为0,1,2或3。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式